Tune Therapeutics isn’t the only Triangle biotech startup to have recently raised north of $100 million. In August, the Research Triangle Park-based company Pathalys Pharma secured $105 ...

Tune Therapeutics, a biotech company with headquarters in Seattle and Durham, N.C., raised $175 million in one of the largest funding rounds for a Seattle-area startup in recent years.

Tune Therapeutics isn’t the only Triangle biotech startup to have recently raised north of $100 million. In August, the Research Triangle Park-based company Pathalys Pharma secured $105 ...

Tune Therapeutics, a Durham biotechnology startup co-founded by a Duke professor, announced the completion of its Series B fundraising round on Jan. 12, in which it raised $175 million to support ...

This year, Tune Therapeutics Principal Scientist Brian Cosgrove shared new in vitro and in vivo data, showcasing Tune’s clinically optimized liver-targeting LNP-RNA epi-silencing drug (Tune-401 ...

DURHAM, N.C. & SEATTLE, January 13, 2025--Leading epigenome editing company Tune Therapeutics (Tune) today announced the completion of over $175M in financing led by New Enterprise Associates ...

A new CEO is leading a Durham biotechnology company that recently closed a $175 million funding round.

Tune Therapeutics is pioneering a new therapeutic modality (termed epigenome editing or genetic tuning) that enables the targeted control of gene expression without cutting or resequencing DNA.

Dr. Fyodor Urnov is a Professor of Genetics, Genomics, and Development at UC Berkeley and Scientific Director at the Innovative Genomics Institute, and a Co-Founder of Tune Therapeutics. His work ...